With Sights Set on Assay-Specific Devices, Newomics Builds MEA Chip for Diabetes Monitoring | GenomeWeb

Using its multinozzle emitter array technology, biotech firm Newomics has developed a top-down proteomics assay for diabetes monitoring.

The assay measures glucose along with the intact forms of glycated hemoglobin, glycated HSA, and glycated apolipoprotein A-I for monitoring blood sugar, as well as intact cysteinylated HSA, S-nitrosylated HbA, and methionine-oxidized apoA-I to gauge oxidative stress and cardiovascular risk.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.